

Pubblicazioni¹⁻⁵⁷

1. Prete AA, Manca P, Messina M, et al. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. *Eur J Cancer*. 2023;182:87-97.
2. Petrelli A, Rizzolio S, Pietrantonio F, et al. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. *Cancer Res*. 2023;83(10):1699-1710.
3. Nappo F, Fornaro L, Pompella L, et al. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. *J Cancer Res Clin Oncol*. 2023.
4. Moretto R, Germani MM, Giordano M, et al. Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. *British journal of cancer*. 2023;128(7):1391-1399.
5. Castagnoli L, Corso S, Franceschini A, et al. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. *Cell Oncol (Dordr)*. 2023;46(3):661-676.
6. Rosati G, Cella CA, Cavanna L, et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial. *Gastric Cancer*. 2022;25(4):783-793.
7. Raimondi A, Randon G, Prisciandaro M, et al. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. *International journal of cancer*. 2022;151(10):1760-1769.
8. Prisciandaro M, Antista M, Raimondi A, et al. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. *Front Oncol*. 2022;12:780716.
9. Niger M, Nichetti F, Casadei-Gardini A, et al. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. *Mol Oncol*. 2022;16(14):2733-2746.
10. Morano F, Raimondi A, Pagani F, et al. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2022;40(14):1562-1573.
11. Marmorino F, Prisciandaro M, Giordano M, et al. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. *JCO Precis Oncol*. 2022;6:e2200244.
12. Manca P, Corallo S, Lonardi S, et al. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. *British journal of cancer*. 2022;126(3):449-455.
13. Innocenzi V, Zueva SB, Ippolito NM, Ferella F, Prisciandaro M, Veglio F. A review of the existing and emerging technologies for wastewaters containing tetramethyl ammonium hydroxide (TMAH) and waste management systems in micro-chip microelectronic industries. *Chemosphere*. 2022;307(Pt 2):135913.
14. Fuca G, Raimondi A, Prisciandaro M, et al. Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. *Oncologist*. 2022;27(1):e29-e36.
15. Antoniotti C, Marmorino F, Boccaccino A, et al. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. *Eur J Cancer*. 2022;165:116-124.
16. Ughetto S, Migliore C, Pietrantonio F, et al. Personalized therapeutic strategies in HER2-driven gastric cancer. *Gastric Cancer*. 2021;24(4):897-912.
17. Raimondi A, Palermo F, Prisciandaro M, et al. Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers (Basel)*. 2021;13(11).
18. Raimondi A, Corallo S, Lonardi S, et al. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Support Care Cancer*. 2021;29(7):3971-3980.
19. Prinzi N, Rossi RE, Proto C, et al. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. *Clinical lung cancer*. 2021;22(3):161-169.
20. Pietrantonio F, Fuca G, Manca P, et al. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. *Tumori*. 2021;107(4):353-359.
21. Manca P, Corallo S, Randon G, et al. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *Eur J Cancer*. 2021;144:31-40.
22. Manca P, Corallo S, Busico A, et al. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2021;27(9):2505-2514.

23. Lonardi S, Prete AA, Morano F, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. *J Immunother Cancer*. 2021;9(11).
24. Giommoni E, Lavacchi D, Tirino G, et al. Results of the observational prospective RealFLOT study. *BMC Cancer*. 2021;21(1):1086.
25. Fuca G, Corti F, Ambrosini M, et al. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. *J Immunother Cancer*. 2021;9(4).
26. Corso S, Pietrantonio F, Apicella M, et al. Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2021;27(11):3126-3140.
27. Vernieri C, Prisciandaro M, Nichetti F, et al. Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. *Cancers (Basel)*. 2020;12(3).
28. Ruzzo A, Graziano F, Bagaloni I, et al. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. *Gastric Cancer*. 2020;23(6):1064-1074.
29. Rossini D, Germani MM, Pagani F, et al. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clinical colorectal cancer*. 2020;19(3):191-199 e196.
30. Pusceddu S, Vernieri C, Prinzi N, et al. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. *Therap Adv Gastroenterol*. 2020;13:1756284820927271.
31. Pusceddu S, Rossi RE, Torchio M, et al. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. *J Clin Med*. 2020;9(8).
32. Pietrantonio F, Morano F, Niger M, et al. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clinical colorectal cancer*. 2020;19(3):156-164.
33. Pietrantonio F, Loupakis F, Randon G, et al. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*. 2020;25(9):803-809.
34. Niger M, Prisciandaro M, Antista M, et al. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. *World J Gastrointest Oncol*. 2020;12(8):833-849.
35. Moretto R, Corallo S, Belfiore A, et al. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *Eur J Cancer*. 2020;135:78-88.
36. Lobefaro R, Zattarin E, Nichetti F, et al. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. *Ther Adv Med Oncol*. 2020;12:1758835920970081.
37. Graziano F, Fischer NW, Bagaloni I, et al. TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. *Cancers (Basel)*. 2020;12(8).
38. Corallo S, Fuca G, Morano F, et al. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. *Oncologist*. 2020;25(9):780-786.
39. Vernieri C, Prisciandaro M, Milano M, et al. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. *Clin Breast Cancer*. 2019;19(2):e306-e318.
40. Vernieri C, Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. *Crit Rev Oncol Hematol*. 2019;139:53-66.
41. Prisciandaro M, Ratta R, Massari F, et al. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. *Am J Clin Oncol*. 2019;42(1):42-45.
42. Pietrantonio F, Cotsoglou C, Fuca G, et al. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. *Clinical colorectal cancer*. 2019;18(1):34-43 e36.
43. Peverelli G, Raimondi A, Ratta R, et al. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. *Clin Genitourin Cancer*. 2019;17(4):291-298.
44. Pagani F, Randon G, Guarini V, et al. The Landscape of Actionable Gene Fusions in Colorectal Cancer. *Int J Mol Sci*. 2019;20(21).
45. Miscio G, Paroni G, Bisceglia P, et al. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. *Expert Opin Drug Metab Toxicol*. 2019;15(9):751-765.
46. Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. *J Cancer Res Clin Oncol*. 2019;145(2):511-521.

47. Indini A, Di Guardo L, Cimminiello C, et al. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. *Tumori*. 2019;105(6):465-473.
48. Cimminiello C, Indini A, Di Guardo L, et al. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. *Melanoma Res*. 2019;29(3):289-294.
49. Vernieri C, Mennitto A, Prisciandaro M, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep*. 2018;8(1):8703.
50. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clin Genitourin Cancer*. 2018;16(4):e945-e951.
51. Pietrantonio F, Fuca G, Morano F, et al. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2018;24(5):1082-1089.
52. Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2018;29(6):1394-1401.
53. Pietrantonio F, Barretta F, Fanotto V, et al. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*. 2018;95(6):344-352.
54. Cremolini C, Milione M, Marmorino F, et al. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *British journal of cancer*. 2018;118(7):955-965.
55. Grassi P, Verzoni E, Ratta R, et al. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? *Drugs R D*. 2017;17(3):461-467.
56. Cremolini C, Pietrantonio F, Tomasello G, et al. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*. 2017;2(3):e000241.
57. Mennitto A, Grassi P, Ratta R, Verzoni E, Prisciandaro M, Procopio G. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. *Ther Adv Urol*. 2016;8(5):319-326.